We also present preclinical data on the radiopharmacological profile of [18F]DCFPyL in PSMA+ LNCaP and PSMA− PC3 tumor xenografts which further confirmed the quality of the resulting radiotracer for targeted molecular imaging of PSMA in prostate cancer. This evidence concerns the gene FOLH1 and prostate carcinoma.